EKF Diagnostics Investor Announcements
EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.
Final results for the year ended 31 December 2021.
Additional enzyme production capacity to accelerate EKF’s organic growth strategy
EKF notes the announcements released by Verici Dx plc on 4 March 2022 relating to the successful Placing for Verici Dx, a developer of advanced clinical diagnostics for organ transplant.
EKF will announce its preliminary results for the year ended 31 December 2021 on Tuesday 29 March 2022.
EKF announces the appointment of Jenny Winter as Non-executive Director (“NED”), effective on 1 February 2022. At the same time Carl Contadini, Non-executive Director, will stand down from the Board.
EKF confirms that continued strong trading will result in its performance for the financial year ended 31 December 2021, including adjusted EBITDA, being ahead of already upgraded market expectations.
Collaboration to broaden testing capabilities through EKF’s accredited US laboratory beyond COVID-19
Appointment of Chief Financial Officer